PLRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Pliant Therapeutics Inc (PLRX) is not a compelling buy for a beginner investor with a long-term horizon at this time. The stock lacks strong positive catalysts, has weak financial performance, and no significant trading signals or news to suggest immediate upside potential.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 48.462, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 1.321, with key resistance at 1.365 and support at 1.277.
Hedge funds are increasing their buying activity by 138.46%, and the company has sufficient cash to fund operations into 2H28.
Analysts have lowered price targets to $3, citing weak financial performance and a long timeline for meaningful data from clinical trials. No recent news or congress trading activity to drive sentiment.
In Q4 2025, revenue remained at $0 with no growth. Net income dropped significantly by -52.59% YoY to -$23.58M, and EPS fell by -53.66% YoY to -$0.38. Gross margin remains at 0%.
Analysts have lowered price targets from $4 to $3. Canaccord maintains a Hold rating, while Piper Sandler keeps an Overweight rating but highlights a long development timeline for key programs.
